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Expansion of Intronic GGCCTG Hexanucleotide Repeat
in NOP56 Causes SCA36, a Type of Spinocerebellar Ataxia
Accompanied by Motor Neuron Involvement
Hatasu Kobayashi,1,4 Koji Abe,2,4 Tohru Matsuura,2,4 Yoshio Ikeda,2 Toshiaki Hitomi,1 Yuji Akechi,2
Toshiyuki Habu,3 Wanyang Liu,1 Hiroko Okuda,1 and Akio Koizumi1,*
Autosomal-dominant spinocerebellar ataxias (SCAs) are a heterogeneous group of neurodegenerative disorders. In this study, we per-
formed genetic analysis of a unique form of SCA (SCA36) that is accompanied by motor neuron involvement. Genome-wide linkage
analysis and subsequent fine mapping for three unrelated Japanese families in a cohort of SCA cases, in whom molecular diagnosis
had never been performed, mapped the disease locus to the region of a 1.8 Mb stretch (LOD score of 4.60) on 20p13 (D20S906–
D20S193) harboring 37 genes with definitive open reading frames. We sequenced 33 of these and observed a large expansion of an
intronic GGCCTG hexanucleotide repeat in NOP56 and an unregistered missense variant (Phe265Leu) in C20orf194, but we found
no mutations in PDYN and TGM6. The expansion showed complete segregation with the SCA phenotype in family studies, whereas
Phe265Leu in C20orf194 did not. Screening of the expansions in the SCA cohort cases revealed four additional occurrences, but
none were revealed in the cohort of 27 Alzheimer disease cases, 154 amyotrophic lateral sclerosis cases, or 300 controls. In total,
nine unrelated cases were found in 251 cohort SCA patients (3.6%). A founder haplotype was confirmed in these cases. RNA foci forma-
tionwas detected in lymphoblastoid cells from affected subjects by fluorescence in situ hybridization. Double staining and gel-shift assay
showed that (GGCCUG)n binds the RNA-binding protein SRSF2 but that (CUG)6 does not. In addition, transcription of MIR1292,
a neighboring miRNA, was significantly decreased in lymphoblastoid cells of SCA patients. Our finding suggests that SCA36 is caused
by hexanucleotide repeat expansions through RNA gain of function.Autosomal-dominant spinocerebellar ataxias (SCAs) are
a heterogeneous group of neurodegenerative disorders
characterized by loss of balance, progressive gait, and
limb ataxia.1–3 We recently encountered two unrelated
patients with intriguing clinical symptoms from a commu-
nity in the Chugoku region in western mainland Japan.4
These patients both showed complicated clinical features,
with ataxia as the first symptom, followed by characteristic
late-onset involvement of the motor neuron system that
caused symptoms similar to those of amyotrophic lateral
sclerosis (ALS [MIM 105400]).4 Some SCAs (SCA1 [MIM
164400], SCA2 [MIM 183090], SCA3 [MIM 607047], and
SCA6 [MIM 183086]) are known to slightly affect motor
neurons; however, their involvement is minimal and the
patients usually do not develop skeletal muscle and tongue
atrophies.4 Of particular interest is that RNA foci have been
recently demonstrated in hereditary disorders caused by
microsatellite repeat expansions or insertions in the non-
coding regions of their gene.5–7 The unique clinical features
in these families have seldom been described in previous
reports; therefore, we undertook a genetic analysis.
A similar form of SCAwas observed in five Japanese cases
from a cohort of 251 patients with SCA, in whom molec-
ular diagnosis had not been performed, who were followed
by the Department of Neurology, Okayama University
Hospital. These five cases originated from a city of
450,000 people in the Chugoku region. Thus, we suspected1Department of Health and Environmental Sciences, Graduate School of Med
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4These authors contributed equally to this work
*Correspondence: koizumi.akio.5v@kyoto-u.ac.jp
DOI 10.1016/j.ajhg.2011.05.015. 2011 by The American Society of Human
The Amthe presence of a founder mutation common to these five
cases, prompting us to recruit these five families (pedigrees
1–5) (Figure 1, Table 1). This study was approved by the
Ethics Committee of Kyoto University and the Okayama
University institutional review board. Written informed
consent was obtained from all subjects. An index of cases
per family was investigated in some depth: IV-4 in pedigree
1, II-1 in pedigree 2, III-1 in pedigree 3, II-1 in pedigree 4,
and II-1 in pedigree 5. The mean age at onset of cerebellar
ataxia was 52.8 5 4.3 years, and the disease was trans-
mitted by an autosomal-dominant mode of inheritance.
All affected individuals started their ataxic symptoms,
such as gait and truncal instability, ataxic dysarthria, and
uncoordinated limbs, in their late forties to fifties. MRI
revealed relatively confined and mild cerebellar atrophy
(Figure 2A). Unlike individuals with previously known
SCAs, all affected individuals with longer disease duration
showed obvious signs of motor neuron involvement
(Table 1). Characteristically, all affected individuals ex-
hibited tongue atrophy with fasciculation, although its
degree of severity varied (Figure 2B). Despite severe tongue
atrophy in some cases, their swallowing function was rela-
tively preserved, and they were allowed oral intake even at
a later point after onset. In addition to tongue atrophy,
skeletal muscle atrophy and fasciculation in the limbs
and trunk appeared in advanced cases.4 Tendon reflexes
were generally mildly to severely hyperreactive in mosticine, Kyoto University, Kyoto, Japan; 2Department of Neurology, Graduate
sity, Okayama, Japan; 3Radiation Biology Center, Kyoto University, Kyoto,
Genetics. All rights reserved.
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Figure 1. Pedigree Charts of the Five SCA Families
Haplotypes are shown for nine markers from D20S906 (1,505,576 bp) to D20S193 (3,313,494 bp), spanning 1.8 Mb on chromosome
20p13.NOP56 is located at 2,633,254–2,639,039 bp (NCBI build 37.1). Filled and unfilled symbols indicate affected and unaffected indi-
viduals, respectively. Squares and circles represent males and females, respectively. A slash indicates a deceased individual. The putative
founder haplotypes among patients are shown in boxes constructed by GENHUNTER.8 Arrows indicate the index case. The pedigrees
were slightly modified for privacy protection.
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Table 1. Clinical Characteristics of Affected Subjects
Pedigree
No.
Patient
ID Gender
Onset
Age (yr)
Current
Age (yr) Ataxia
Motor Neuron Involvement
Genotype of GGCCTG Repeats
Skeletal
Muscle
Atrophy
Skeletal
Muscle
Fasciculation
Tongue
Atrophy/
Fasciculation
1 III-5 M 50 70 þþþ N.D. N.D. N.D. g.263397_263402[6]þ(1800)
III-6 F 52 68 þþ þ þ þ g.263397_263402[6]þ(2300)
IV-2 F 57 63 þ - - þ g.263397_263402[6]þ(2300)
IV-4 M 50 59 þ - - þ g.263397_263402[6]þ(2300)
2 II-1 M 55 77 þþþ þþ þ þ g.263397_263402[6]þ(2200)
II-2 F 53 70 þþ N.D. N.D. N.D. g.263397_263402[6]þ(2200)
3 II-3 M 58 77 þþ þþ þ þ g.263397_263402[3]þ(2300)
III-1 M 56 62 þ - - 5 g.263397_263402[8]þ(2200)
III-2 M 51 61 þþ þ þ þ g.263397_263402[6]þ(1800)
4 I-1 M 57 died in
2001 at 83
þþ N.D. N.D. N.D. g.263397_263402[5]þ(1800)
II-1 F 48 61 þþ þ 5 þþ g.263397_263402[6]þ(2000)
5 I-1 M 57 86 þþ þþþ þ þ g.263397_263402[5]þ(2000)
II-1 F 47 58 þþ þ þ þ g.263397_263402[8]þ(1700)
SCA#1 M 52 69 þþþ þþþ þþþ þþþ g.263397_263402[5]þ(2200)
SCA#2 F 43 53 þþþ - - þ g.263397_263402[6]þ(1800)
SCA#3 M 55 60 þþ - - þþ g.263397_263402[8]þ(1700)
SCA#4 M 57 81 þþþ þ þ þþþ g.263397_263402[5]þ(2200)
Mean 52.8
SD 4.3
N.D., not determined.affected individuals, none of whom displayed severe lower
limb spasticity or extensor plantar response. Electrophysi-
ological studies were performed in an affected individual.
Nerve conduction studies revealed normal findings in all
of the cases that were examined; however, an electromyo-
gram showed neurogenic changes only in cases with
skeletal muscle atrophy, indicating that lower motor
neuropathy existed in this particular disease. Progression
of motor neuron involvement in this SCA was typically
limited to the tongue and main proximal skeletal muscles
in both upper and lower extremities, which is clearly
different from typical ALS, which usually involves most
skeletal muscles over the course of a few years, leading to
fatal results within several years.
We conducted genome-wide linkage analysis for nine
affected subjects and eight unaffected subjects in three
informative families (pedigrees 1–3; Figure 1). For genotyp-
ing, we used an ABI Prism Linkage Mapping Set (Version 2;
Applied Biosystems, Foster City, CA, USA) with 382
markers, 10 cM apart, for 22 autosomes. Fine-mapping
markers (approximately 1 cM apart) were designed accord-
ing to information from the uniSTS reference physical map
in the NCBI database. A parametric linkage analysis wasThe Amcarried out in GENEHUNTER8 with the assumption of an
autosomal-dominant model. The disease allele frequency
was set at 0.000001, and a phenocopy frequency of
0.000001 was assumed. Population allele frequencies
were assigned equal portions of individual alleles. We per-
formed multipoint analyses for autosomes and obtained
LOD scores. We considered LOD scores above 3.0 to be
significant.8 Genome-wide linkage analysis revealed
a single locus on chromosome 20p13 with a LOD score
of 3.20. Fine mapping increased the LOD score to 4.60
(Figure 3). Haplotype analysis revealed two recombination
events in pedigree 3, delimiting a1.8 Mb region (D20S906–
D20S193) (Figure 1). We further tested whether the five
cases shared the haplotype. As shown in Figure 1, pedigrees
4 and 5 were confirmed to have the same haplotype as
pedigrees 1, 2, and 3, indicating that the 1.8 Mb region is
very likely to be derived from a common ancestor.
The1.8Mbregionharbors44genes (NCBI,build37.1).We
eliminated two pseudogenes and five genes (LOC441938,
LOC100289473, LOC100288797, LOC100289507, and
LOC100289538) from the candidates. Evidence view
showed that the first, fourth, and fifth genes were not found
in the contig in this region, whereas the second and thirderican Journal of Human Genetics 89, 121–130, July 15, 2011 123
Figure 2. Motor Neuron Involvement and (GGCCTG)n Expansion in the First Intron of NOP56
(A) MRI of an affected subject (SCA#3) showed mild cerebellar atrophy (arrow) but no other cerebral or brainstem pathology.
(B) Tongue atrophy (arrow) was observed in SCA#1.
(C) Physicalmap of the 1.8-Mb linkage region fromD20S906 (1,505,576 bp) to D20S193 (3,313,494 bp), with 33 candidate genes shown,
as well as the direction of transcription (arrows).
(D) The upper portion of the panel shows the scheme of primer binding for repeat-primer PCR analysis. In the lower portion, sequence
traces of the PCR reactions are shown. Red lines indicate the size markers. The vertical axis indicates arbitrary intensity levels. A typical
saw-tooth pattern is observed in an affected pedigree.
(E) Southern blotting of LCLs from SCA cases and three controls. Genomic DNA (10 mg) was extracted from Epstein-Barr virus (EBV)-
immortalized LCLs derived from six affected subjects (Ped2_II-1, Ped3_III-1, Ped3_III-2, Ped5_I-1, Ped5_II-1, and SCA#1) and digested
with 2 U of AvrII overnight (New England Biolabs, Beverly, MA, USA). A probe covering exon 4 of NOP56 (452 bp) was subjected to
PCR amplification from human genomic DNA with the use of primers (Table S3) and labeled with 32P-dCTP.genes are not assigned to orthologous loci in the mouse
genome. Sequence similarities among paralog genes defied
direct sequencing of four genes: SIRPD [NM 178460.2],
SIRPB1 [NM 603889], SIRPG [NM 605466], and SIRPA
[NM 602461]. Thus, we sequenced 33 of 37 genes (PDYN
[MIM 131340], STK35 [MIM 609370], TGM3 [MIM
600238], TGM6 [NM_198994.2], SNRPB [MIM 182282],
SNORD119 [NR_003684.1], ZNF343 [NM_024325.4],
TMC2 [MIM 606707], NOP56 [NM_006392.2], MIR1292
[NR_031699.1], SNORD110 [NR_003078.1], SNORA51
[NR_002981.1], SNORD86 [NR_004399.1], SNORD56
[NR_002739.1], SNORD57 [NR_002738.1], IDH3B [MIM
604526], EBF4 [MIM 609935], CPXM1 [NM_019609.4],
C20orf141 [NM_080739.2], FAM113A [NM_022760.3],124 The American Journal of Human Genetics 89, 121–130, July 15, 2VPS16 [MIM 608550], PTPRA [MIM 176884], GNRH2
[MIM 602352], MRPS26 [MIM 611988], OXT [MIM
167050], AVP [MIM 192340], UBOX5 [NM_014948.2],
FASTKD5 [NM_021826.4], ProSAPiP1 [MIM 610484],
DDRGK1 [NM_023935.1], ITPA [MIM 147520], SLC4A11
[MIM 610206], and C20orf194 [NM_001009984.1]) (Fig-
ure 2C). All noncoding and coding exons, as well as the
100 bp up- and downstream of the splice junctions of these
genes, were sequenced in two index cases (IV-4 in pedigree1
and III-1 in pedigree 3) and in three additional cases (II-1 in
pedigree 2, II-1 in pedigree 4, and II-1 in pedigree 5)with the
use of specific primers (Table S1 available online). Eight
unregistered variants were found among the two index
cases. Among these, there was a coding variant, c.795C>G011
Figure 3. Multipoint Linkage Analysis with Ten Markers on
Chromosome 20p13(p.Phe265Leu), in C20orf194, whereas the other seven
included one synonymous variant, c.1695T>A (p.Leu565-
Leu), in ZNF343 and six non-splice-site intronic variants
(Table S2). We tested segregation by sequencing exon 11 of
C20orf194 in IV-2 and III-5 in pedigree 1. Neither IV-2 nor
III-5 had this variant. We thus eliminated C20orf194 as
a candidate.Missensemutations inPDYN andTGM6, which
have been recently reported as causes of SCA, mapped to
20p12.3-p13,9,10 but none were detected in the five index
cases studied here (Table S2).
Possible expansions of repetitive sequences in these
33 genes were investigated when intragenic repeats
were indicated in the database (UCSC Genome Bioinfor-
matics). Expansions of the hexanucleotide repeat
GGCCTG (rs68063608) were found in intron 1 of NOP56
(Figure 2D) in all five index cases through the use of
a repeat-primed PCR method.11–13 An outline of the
repeat-primed PCR experiment is described in Figure 2D.
In brief, the fluorescent-dye-conjugated forward primer
corresponded to the region upstream of the repeat of
interest. The first reverse primer consisted of four units of
the repeat (GGCCTG) and a 50 tail used as an anchor.
The second reverse primer was an ‘‘anchor’’ primer. These
primers are described in Table S3. Complete segregation
of the expanded hexanucleotide was confirmed in all pedi-
grees, and the maximum repeat size in nine unaffected
members was eight (data not shown).
In addition to the SCA cases in five pedigrees, four
unrelated cases (SCA#1–SCA#4) were found to have a
(GGCCTG)n allele through screening of the cohort SCA
patients (Table 1). Neurological examination was reeval-
uated in these four cases, revealing both ataxia and motor
neuron dysfunctionwith tongue atrophy and fasciculation
(Table 1). In total, nine unrelated cases were found in the
251 cohort patients with SCA (3.6%). For confirmation of
the repeat expansions, Southern blot analysis was conduct-
ed in six affected subjects (Ped2_II-1, Ped3_III-1, Ped3_III-2,
Ped5_I-1, Ped5_II-1, and SCA#1). The data showed >10 kb
of repeat expansions in the lymphoblastoid cell linesThe Am(LCLs) obtained from the SCA patients (Figure 2E). Further-
more, the numbers of GGCCTG repeat expansion were
estimated by Southern blotting in 11 other cases. The
expansion analysis revealed approximately 1500 to 2500
repeats in 17 cases (Table 1). There was no negative associa-
tion between age at onset and the number of GGCCTG
repeats (n¼17, r¼0.42, p¼0.09; Figure S1) andnoobvious
anticipation in the current pedigrees.
To investigate the disease specificity and disease spec-
trum of the hexanucleotide repeat expansions, we tested
the repeat expansions in an Alzheimer disease (MIM
104300) cohort and an ALS cohort followed by the Depart-
ment of Neurology, Okayama University Hospital. We also
recruited Japanese controls, who were confirmed to be free
from brain lesions through MRI and magnetic resonance
angiography, which was performed as described previ-
ously.14 Screening of the 27 Alzheimer disease cases and
154 ALS cases failed to detect additional cases with repeat
expansions. The GGCCTG repeat sizes ranged from 3 to
8 in 300 Japanese controls (5.9 5 0.8 repeats), suggesting
that the >10 kb repeat expansions were mutations.
Expression of Nop56, an essential component of the
splicing machinery,15 was examined by RT-PCR with the
use of primers for wild-type mouse Nop56 cDNA (Table
S3). Expression of Nop56 mRNA was detected in various
tissues, including CNS tissue, and a very weak signal was
detected in spinal cord tissue (Figure 4A). Immunohisto-
chemistry using an anti-mouse Nop56 antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) detected the
Nop56 protein in Purkinje cells of the cerebellum as well
as motor neurons of the hypoglossal nucleus and the
spinal cord anterior horn (Figure 4B), suggesting that these
cells may be responsible for tongue and muscle atrophy in
the trunk and limbs, respectively. Immunoblotting also
confirmed the presence of Nop56 in neural tissues
(Figure 4C), where Nop56 is localized in both the nucleus
and cytoplasm.
Alterations of NOP56 RNA expression and protein levels
in LCLs from patients were examined by real-time RT-PCR
and immunoblotting. The primers for quantitative PCR of
human NOP56 cDNA are described in Table S3. Immuno-
blotting was performed with the use of an anti-human
NOP56 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). We found no decrease inNOP56 RNA expression
or protein levels in LCLs from these patients (Figure 5A). To
investigate abnormal splicing variants of NOP56, we per-
formed RT-PCR using the primers covering the region
from the 50 UTR to exon 4 around the repeat expansion
(Table S3); however, no splicing variant was observed in
LCLs from the cases (Figure 5B). We also performed immu-
nocytochemistry for NOP56 and coilin, a marker of the
Cajal body, where NOP56 functions.16 NOP56 and coilin
distributions were not altered in LCLs of the SCA patients
(Figure 5C), suggesting that qualitative or quantitative
changes in the Cajal body did not occur. These results indi-
cated that haploinsufficiency could not explain the
observed phenotype.erican Journal of Human Genetics 89, 121–130, July 15, 2011 125
Figure 4. Nop56 in the Mouse Nervous System
(A) RT-PCR analysis of Nop56 (422 bp) in various mouse tissues. cDNA (25 ng) collected from various organs of C57BL/6 mice was
purchased from GenoStaf (Tokyo, Japan).
(B) Immunohistochemical analysis of Nop56 in the cerebellum, hypoglossal nucleus, and spinal cord anterior horn in wild-type male
Slc:ICR mice at 8 wks of age (Japan SLC, Shizuoka, Japan). The arrows indicate anti- Nop56 antibody staining. The negative control
was the cerebellar sample without the Nop56 antibody treatment. Scale bar represents 100 mm.
(C) Immunoblotting of Nop56 (66 kDa) in the cerebellum and cerebrum. Protein sample (10 mg) was subjected to immunoblotting.
LaminB1, a nuclear protein, and beta-tubulin were used as loading controls.We performed fluorescence in situ hybridization to
detect RNA foci containing the repeat transcripts in LCLs
from patients, as previously described.17,18 Lymphoblas-
toid cells from two SCA patients (Ped2_II-2 and Ped5_I-1)
and two control subjects were analyzed. An average of
2.1 5 0.5 RNA foci per cell were detected in 57.0%
of LCLs (n ¼ 100) from the SCA subjects through the use
of a nuclear probe targeting the GGCCUG repeat, whereas
no RNA foci were observed in control LCLs (n ¼ 100)
(Figure 6A). In contrast, a probe for the CGCCUG repeat,
another repeat sequence in intron 1 of NOP56, detected
no RNA foci in either SCA or control LCLs (n ¼ 100
each) (Figure 6A), indicating that the GGCCUG repeat
was specifically expanded in the SCA subjects. The speci-
ficity of the RNA foci was confirmed by sensitivity to RNase
A treatment and resistance to DNase treatment (Figure 6A).
Several reports have suggested that RNA foci play a role
in the etiology of SCA through sequestration of specific
RNA-binding proteins.5–7 In silico searches (ESEfinder
3.0) predicted an RNA-binding protein, SRSF2 (MIM
600813), as a strong candidate for binding of the GGCCUG
repeat. Double staining with the probe for the GGCCUG
repeat and an anti-SRSF2 antibody (Sigma-Aldrich, Tokyo,
Japan) was performed. The results showed colocalization of
RNA foci with SRSF2, whereas NOP56 and coilin were not126 The American Journal of Human Genetics 89, 121–130, July 15, 2colocalized with the RNA foci (Figure 6B), suggesting
a specific interaction of endogenous SRSF2 with the RNA
foci in vivo.
To further confirm the interaction, gel-shift assays were
carried out for investigation of the binding activity of
SRSF2 with (GGCCUG)n. Synthetic RNA oligonucleotides
(200 pmol), (GGCCUG)4 or (CUG)6, which is the latter
part of the hexanucleotide, as well as the repeat RNA
involved in myotonic dystrophy type 1 (DM1 [MIM
160900])18 and SCA8 (MIM 608768),5 were denatured
and immediately mixed with different amounts (0, 0.2,
or 0.6 mg) of recombinant full-length human SRSF2
(Abcam, Cambridge, UK). The mixtures were incubated,
and the protein-bound probes were separated from the
free forms by electrophoresis on 5%–20% native polyacryl-
amide gels. The separated RNA probes were detected with
SYBR Gold staining (Invitrogen, Carlsbad, CA, USA). We
found a strong association of (GGCCUG)4 with SRSF2
in vitro in comparison to (CUG)6 (Figure 6C). Collectively,
we concluded that (GGCCUG)n interacts with SRSF2.
It is notable that MIR1292 is located just 19 bp 30 of the
GGCCTG repeat (Figure 2D). MiRNAs such asMIR1292 are
small noncoding RNAs that regulate gene expression by in-
hibiting translation of specific target mRNAs.19,20 MiRNAs
are believed to play important roles in key molecular011
Figure 5. Analysis of NOP56 in LCLs from
SCA Patients
(A) mRNA expression (upper panel) and
protein levels (lower panel) in LCLs from
cases (n ¼ 6) and controls (n ¼ 3) were
measured by RT-PCR and immunoblotting,
respectively. cDNA (10 ng) was transcribed
from total RNA isolated from LCLs and
used for RT-PCR. Immunoblotting was per-
formed with the use of a protein sample
(40 mg) extracted from LCLs. The data indi-
cate the mean5 SD relative to the levels of
PP1A and GAPDH, respectively. There was
no significant difference between LCLs
from controls and cases.
(B) Analysis for splicing variants of NOP56
cDNA. RT-PCR with 10 ng of cDNA and
primers corresponding to the region from
the 50 UTR to exon 4 around the repeat
expansion was performed. The PCR
product has an expected size of 230 bp.
(C) Immunocytochemistry for NOP56 and
coilin. Green signals represent NOP56 or
coilin. Shown are representative samples
from 100 observations of controls or cases.pathways by fine-tuning gene expression.19,20 Recent
studies have revealed that miRNAs influence neuronal
survival and are also associated with neurodegenerative
diseases.21,22 In silico searches (Target Scan Human 5.1)
predicted glutamate receptors (GRIN2B [MIM 138252]
and GRIK3 [MIM 138243]) to be potential target genes.
Real-time RT-PCR using TaqMan probes for miRNA
(Invitrogen, Carlsbad, CA, USA) revealed that the levels
of both mature and precursor MIR1292 were significantly
decreased in SCA LCLs (Figure 6D), indicating that the
GGCCTG repeat expansion decreased the transcription
of MIR1292. A decrease in MIR1292 expression may
upregulate glutamate receptors in particular cell types;
e.g., GRIK3 in stellate cells in the cerebellum,23 leading to
ataxia because of perturbation of signal transduction to
the Purkinje cells. In addition, it has been suggested, on
the basis of ALS mouse models,24,25 that excitotoxicity
mediated by a type of glutamate receptor, the NMDA
receptor including GRIN2B, is involved in loss of spinal
neurons. A very slowly progressing and mild form of the
motor neuron disease, such as that described here, which
is limited to mostly fasciculation of the tongue, limbs
and trunk, may also be compatible with such a functional
dysregulation rather than degeneration.
In the present study, we have conducted genetic analysis
to find a genetic cause for the unique SCA with motor
neuron disease. With extensive sequencing of the 1.8 Mb
linked region, we found large hexanucleotide repeat
expansions in NOP56, which were completely segregated
with SCA in five pedigrees and were found in four unre-
lated cases with a similar phenotype. The expansion was
not found in 300 controls or in other neurodegenerative
diseases. We further proved that repeat expansions ofThe AmNOP56 induce RNA foci and sequester SRSF2. We thus
concluded that hexanucleotide repeat expansions are
considered to cause SCA by a toxic RNA gain-of-function
mechanism, and we name this unique SCA as SCA36.
Haplotype analysis indicates that hexanucleotide expan-
sions are derived from a common ancestor. The prevalence
of SCA36 was estimated at 3.6% in the SCA cohort in
Chugoku district, suggesting that prevalence of SCA36
may be geographically limited to the western part of Japan
and is rare even in Japanese SCAs.
Expansion of tandem nucleotide repeats in different
regions of respective genes (most often the triplets CAG
and CTG) has been shown to cause a number of inherited
diseases over the past decades. An expansion in the coding
region of a gene causes a gain of toxic function and/or
reduces the normal function of the corresponding protein
at the protein level. RNA-mediated noncoding repeat
expansions have also been identified as causing eight other
neuromuscular disorders: DM1, DM2 (MIM 602668),
fragile X tremor/ataxia syndrome (FXTAS [MIM 300623]),
Huntington disease-like 2 (HDL2 [MIM 606438]), SCA8,
SCA10 (MIM 603516), SCA12 (MIM 604326), and SCA31
(MIM 117210).26 The repeat numbers in affected alleles
of SCA36 are among the largest seen in this group of
diseases (i.e., there are thousands of repeats). Moreover,
SCA36 is notmerely a nontriplet repeat expansion disorder
similar to SCA10, DM2, and SCA31, but is now proven to
be a human disease caused by a large hexanucleotide
repeat expansion. In addition, no or only weak anticipa-
tion has been reported for noncoding repeat expansion
in SCA, whereas clear anticipation has been reported for
most polyglutamine expansions in SCA.2 As such, absence
of anticipation in SCA36 is in accord with previous studieserican Journal of Human Genetics 89, 121–130, July 15, 2011 127
Figure 6. RNA Foci Formation and Decreased Transcription of MIR1292
(A) Cells were fixed on coverslips and then hybridized with solutions containing either a Cy3-labeled C(CAGGCC)2CAG or
G(CAGGCG)2CAG oligonucleotide probe (1 ng/ml). For controls, the cells were treated with 1000 U/ml DNase or 100 mg/ml RNase
for 1 hr at 37C prior to hybridization, as indicated. After a wash step, coverslips were placed on the slides in the presence of ProLong
Gold with DAPI mountingmedia (Molecular Probes, Tokyo, Japan) and photographed with a fluorescence microscope. The upper panels
indicate LCLs from an SCA case and a control hybridized with C(CAGGCC)2CAG (left) or G(CAGGCG)2CAG (right). Red and blue
signals represent RNA foci and the nucleus (DAPI staining), respectively. Similar RNA foci formationwas confirmed in LCLs from another
index case. The lower panels show RNA foci in SCA LCLs treated with DNase or RNase.
(B) Double staining was performed with the probe for (GGCCUG)n (red) and anti-SRSF2, NOP56, or coilin antibody (green).
(C) Gel-shift assays revealed specific binding of SRSF2 to (GGCCUG)4 but little to (CUG)6.
(D) RNA samples (10 ng) were extracted from LCLs of controls (n¼ 3) and cases (n¼ 6).MiRNAsweremeasuredwith the use of a TaqMan
probe for precursor (Pri-) and mature MIR1292. The data indicate the mean5 SD, relative to the levels of PP1A or RNU6. *: p < 0.05.on SCAs with noncoding repeat expansions. The common
hallmark in these noncoding repeat expansion disorders
is transcribed repeat nuclear accumulations with respec-
tive repeat RNA-binding proteins, which are considered
to primarily trigger and develop the disease at the RNA
level. However, multiple different mechanisms are likely
to be involved in each disorder. There are at least two
possible explanations for the motor neuron involvement
of SCA36: gene- and tissue-specific splicing specificity of
SRSF2 and involvement of miRNA. In SCA36, there is the
possibility that the adverse effect of the expansion muta-128 The American Journal of Human Genetics 89, 121–130, July 15, 2tion is mediated by downregulation of miRNA expression.
The biochemical implication of miRNA involvement
cannot be evaluated in this study, because availability of
tissue samples from affected cases was limited to LCLs.
Given definitive downregulation of miRNA 1292 in
LCLs, we should await further study to substantiate its
involvement in affected tissues. Elucidating which mecha-
nism(s) plays a critical role in the pathogenesis will
be required for determining whether cerebellar degenera-
tion and motor neuron disease occur through a similar
scenario.011
In conclusion, expansion of the intronic GGCCTG
hexanucleotide repeat in NOP56 causes a unique form of
SCA, SCA36, which shows not only ataxia but also motor
neuron dysfunction. This characteristic disease phenotype
can be explained by the combination of RNA gain of func-
tion and MIR1292 suppression. Additional studies are
required to investigate the roles of each mechanistic
component in the pathogenesis of SCA36.Supplemental Data
Supplemental Data include one figure and three tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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